Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

NightWare og kardiovaskulær helse hos veteraner med PTSD

6. oktober 2026 oppdatert av: VA Office of Research and Development

Forbedre kardiovaskulær helse hos veteraner med PTSD ved å behandle traumerelaterte mareritt med NightWare

The purpose of this study is to learn more about the effectiveness of a prescription wrist-wearable device called NightWare (NW) on improving sleep in Veterans with nightmares related to posttraumatic stress disorder (PTSD). The investigators also want to learn whether it improves cardiovascular health among this population.

Studieoversikt

Detaljert beskrivelse

Posttraumatic stress disorder (PTSD) is associated with profound health consequences in Veterans, including cardiovascular disease (CVD), the leading cause of death in adults in the United States. Trauma-related nightmares, a hallmark of PTSD, are a debilitating symptom that can lead to poor sleep quality and other health issues that ultimately cause clinically significant impairments in daily functioning. Recently, nightmares were reported to be an independent predictor of CVD in Veterans, for reasons that are unclear. Poor sleep is associated with increased CVD risk, possibly by impairing vascular health and nervous system function. Nightmare-related sleep disturbances are often resistant to first-line treatment (e.g., psychotherapy, medications) and even with improvements, residual nightmares and sleep disturbances often persist that still meet clinical significance. Moreover, significant barriers often exist including access to care and lack of trained providers, that prevent reaching and engagement of individuals to treatments, and there is poor adherence to interventions overall. As such, there is a need to implement interventions and/or complementary approaches that may appeal to Veterans experiencing PTSD-related nightmares who are looking for alternatives. In this regard, NightWare (NW) digital therapeutic is a novel smart watch application that was recently granted Breakthrough Device designation by the FDA for the treatment of nightmares in adults with PTSD. It uses the wearer's biometric data (i.e., heart rate, body movement and position) to distinguish normal and distressed sleep and interrupt nightmares. Preliminary evidence demonstrated an improvement in subjective sleep quality in Veterans after 30-days of NW compared with a sham condition. However, it is unknown whether NW improves sleep quality in Veterans with PTSD with co-morbid medical conditions such as obstructive sleep apnea (OSA) or in those using medications (e.g., prazosin) to treat nightmares related to PTSD. It is also unknown if the effects of NW on sleep are similar in male and female Veterans, or whether improvements in sleep with NW result in improvements in objective sleep (i.e., sleep physiology) or cardiovascular health. In this context, this study will determine if 8 weeks of NW improves subjective sleep in Veterans with PTSD-related nightmares, including those with OSA and/or taking medications to treat PTSD related nightmares (e.g., prazosin). The change in Pittsburgh Sleep Quality Index (PSQI) scores from baseline to 8 weeks will be measured. Additional goals will evaluate changes in cardiovascular health outcomes with NW use and if there are potential sex differences in the response to NW. The proposed research is a high priority topic of the Veterans Affairs, as PTSD affects 11-23% of Veterans in a given year. The research is highly innovative and if successful will lead to significant advances in the healthcare of Veterans, particularly as it relates to the treatment of PTSD-related nightmares.

Studietype

Intervensjonell

Registrering (Antatt)

125

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Colorado
      • Aurora, Colorado, Forente stater, 80045-7211
        • Rekruttering
        • Rocky Mountain Regional VA Medical Center, Aurora, CO
        • Hovedetterforsker:
          • Kerrie L Moreau, PhD
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

22 år til 88 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Diagnosis of Post-traumatic stress disorder (PTSD) via American Psychiatric Association PTSD diagnostic criteria in the fifth edition of its Diagnostic and Statistical Manual of Mental Disorders (DSM-5)
  2. Self-report having repetitive nightmares contributing to disrupted sleep
  3. Resting blood pressure (BP, <160/100 millimeters of mercury (mmHg)
  4. Fasted glucose <126 milligrams per deciliter (mg/dL)
  5. Poor overall sleep quality as indicated by a Pittsburgh Sleep Quality Index (PSQI) score 6 or higher
  6. Epworth Sleepiness Scale (ESS): Question #8 score above "0" will prompt an additional question: Do you drive ("get behind the wheel") when you are drowsy? The answer must be "No" to be enrolled in the study due to safety concerns
  7. Wireless Internet and two power outlets in sleeping location
  8. Willingness not to use any other application which collects heart rate data on the phone and watch that is used for NightWare

Exclusion Criteria:

  1. Unstable medical condition (e.g., uncontrolled hypertension or active Cardiovascular disease (CVD) or cancer)
  2. Active infection (note, anyone with an active infection would become eligible once the infection has ended)
  3. Thyroid dysfunction, defined as an ultrasensitive thyroid stimulating hormone (TSH)<0.5 or >5.0 milliunits per liter (mU/L); volunteers with abnormal thyroid stimulating hormone (TSH) values will be re-considered for participation in the study after follow-up evaluation by the Primary Care Provider (PCP) with initiation or adjustment of thyroid hormone replacement; or other problems that would interfere with participation in the study
  4. Use of insulin or sulfonylureas
  5. Pregnancy or currently breast feeding
  6. Current history (past 3 months) of substance (excluding marijuana) or alcohol abuse per the SCID-5. Adults with past substance or alcohol use disorders will be allowed to participate
  7. Participants will be excluded if they report elevated acute risk for suicidal self-directed violence warranting immediate hospitalization (e.g., suicidal ideation with intent, evaluated by the Columbia-Suicide Severity Rating Scale [C-SSRS])
  8. Shift workers (due to circadian rhythm disruption)
  9. Diagnosis of active disorder of arousal from non-rapid eye movement sleep, rapid eye movement sleep behavior disorder, or narcolepsy;
  10. Nocturia that causes awakening from sleep
  11. Known sleep walking or acting out dreams (contraindication to NightWare (NW) use)
  12. Diagnosis or suspicion of dementia
  13. Seizure disorder
  14. Participants experiencing severe cognitive impairment or current psychiatric symptoms of such severity that would preclude participation (e.g., active psychosis, imminently suicidal)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: NightWare active

Intervention with NightWare Therapeutic System

Nightware intervention app (enabled) will attempt to detect when an individual is having a nightmare based on a Nightware proprietary algorithm and attempt to disrupt the nightmare without awakening. In the sham comparator group the NightWare app will be disabled and not deliver an intervention.

Sham-komparator: NightWare Sham

NightWare app disabled; device will not deliver an intervention

Nightware intervention app (enabled) will attempt to detect when an individual is having a nightmare based on a Nightware proprietary algorithm and attempt to disrupt the nightmare without awakening. In the sham comparator group the NightWare app will be disabled and not deliver an intervention.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Pittsburgh Sleep Quality Index
Tidsramme: Measured before and after 8 weeks of NightWare and sham conditions

Sleep questionnaire with a scale of 0 to 21 with a higher score indicating a significant sleep disturbance

Measured before and after 8 weeks of NightWare and sham conditions

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in physiological sleep - total sleep time
Tidsramme: Measured before and after 8 weeks of NightWare and sham conditions

Total sleep duration (minutes) calculated through ambulatory electroencephalography.

Measured before and after 8 weeks of NightWare and sham conditions
Change in endothelial function
Tidsramme: Measured before and after 8 weeks of NightWare and sham conditions

Brachial artery flow mediated dilation (FMD) using ultrasound

Measured before and after 8 weeks of NightWare and sham conditions
Change in Autonomic function - spontaneous baroreflex sensitivity (BRS)
Tidsramme: Measured before and after 8 weeks of NightWare and sham conditions

Cardiovagal baroreflex sensitivity (cBRS) measured using beat-to-beat time series of systolic blood pressures (finger photo-plethysmography) and R-R interval (three-lead electrocardiogram) will be recorded simultaneously at 1,000 Hz.

Measured before and after 8 weeks of NightWare and sham conditions
Change in large elastic artery stiffness
Tidsramme: Measured before and after 8 weeks of NightWare and sham conditions

Carotid-femoral pulse wave velocity (PWV)

Measured before and after 8 weeks of NightWare and sham conditions
Change in large elastic artery stiffness
Tidsramme: Measured before and after 8 weeks of NightWare and sham conditions

Augmentation index and aortic blood pressure via pulse wave analysis

Measured before and after 8 weeks of NightWare and sham conditions
Change in autonomic function - heart rate variability (HRV)
Tidsramme: Measured before and after 8 weeks of NightWare and sham conditions

Heart rate variability

Measured before and after 8 weeks of NightWare and sham conditions
Change in physiological sleep - wake after sleep onset
Tidsramme: Measured before and after 8 weeks of NightWare and sham conditions

Wake after sleep (minutes) calculated through ambulatory electroencephalography.

Measured before and after 8 weeks of NightWare and sham conditions
Change in physiological sleep - sleep efficiency
Tidsramme: Measured before and after 8 weeks of NightWare and sham conditions

Sleep efficiency (percentage) calculated through ambulatory electroencephalography.

Measured before and after 8 weeks of NightWare and sham conditions
Change in physiological sleep - REM sleep
Tidsramme: Measured before and after 8 weeks of NightWare and sham conditions

REM sleep (minutes) calculated through ambulatory electroencephalography.

Measured before and after 8 weeks of NightWare and sham conditions
Change in physiological sleep - Deep sleep
Tidsramme: Measured before and after 8 weeks of NightWare and sham conditions

Deep sleep (minutes) calculated through ambulatory electroencephalography.

Measured before and after 8 weeks of NightWare and sham conditions
Change in physiological sleep - Light sleep
Tidsramme: Measured before and after 8 weeks of NightWare and sham conditions

Light sleep (minutes) calculated through ambulatory electroencephalography.

Measured before and after 8 weeks of NightWare and sham conditions

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Kerrie L Moreau, PhD, Rocky Mountain Regional VA Medical Center, Aurora, CO

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. september 2025

Primær fullføring (Antatt)

30. september 2027

Studiet fullført (Antatt)

31. desember 2027

Datoer for studieregistrering

Først innsendt

3. mai 2024

Først innsendt som oppfylte QC-kriteriene

14. mai 2024

Først lagt ut (Faktiske)

17. mai 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

8. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

6. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Ja

produkt produsert i og eksportert fra USA

Ja

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere